References
- Choi, S. R., You, D. H., Kim, J. Y., Park, C. B., Kim, D. Y. and Ryu, J. (2009) Antioxidant activity of methanol extracts from Cudrania tricuspidata Bureau according to harvesting parts and time. Korean J. Medicianl Crop. Sci. 17: 115-120.
- Kim, O. K., Ho, J. N., Nam, D. E., Jun, W. J., Hwang, K. T., Kang, J. E., Chae, O. S. and Lee, J. M. (2012) Hepatoprotective effect of Cudrania tricuspidata extracts against oxidative damage. J. Korean Soc. Food Sci. Nutr. 41: 7-13. https://doi.org/10.3746/jkfn.2012.41.1.007
- Lee, H. J., Do, J. R., Kwon, J. H. and Kim, H. Y. (2011) Physiological activities of extracts from different parts of Cudrania tricuspidata. J. Korean Soc. Food Sci. Nutr. 40: 942-948. https://doi.org/10.3746/jkfn.2011.40.7.942
- Kwon, J. Y., Hiep, N., Kim, D. W., Hong, S. G., Guo, Y., Hwang, B. Y., Lee, H. J., Mar, W. C. and Lee, D. H. (2016) Chemical constituents isolated from the root bark of Cudrania tricuspidata and their potential neuroprotective effects. J. Nat. Prod. 79: 1938-1951. https://doi.org/10.1021/acs.jnatprod.6b00204
- Geng, X. L., Yang, L. B., Zhang, C., Qin, H. and Liang, Q, D. (2015) Wogonin inhibits osteoclast differentiation by inhibiting NFATc1 translocation into the nucleus. Exp. Ther. Med. 10: 1066-1070. https://doi.org/10.3892/etm.2015.2615
- Goltzman, D. (2002) Discoveries, drugs and skeletal disorders. Nat. Rev. Drug. Discov. 1: 784-796. https://doi.org/10.1038/nrd916
-
Nie, S. B., Xu, J. W., Zhang, C. H., Xu, C., Liu, M. and Yu, D. G. (2015) Salicortin inhibits osteoclast differentiation and bone resorption by down-reuglating JNK and NF-
${\kappa}B$ / NFATc1 signaling pathways. Biochem. Biophys. Res. Commun. 470: 61-67. - Wu, Y. B., Zheng, C. J., Qin, J. P., Sun, L. N., Han, T., Jiao, L., Zhang, Q. Y. and Wu, J. Z. (2009) Antiosteoporotic activity of anthraquinones from Morinda officinalis on osteoblasts and osteoclasts. Molecules 1: 573-583.
- Murakiami, H., Takahashi, N., Tanaka, S., Nakamura, I., Udagawa, N., Nakajo, S., Nakaya, K., Abe, M., Yuda, Y., Konno, F., Barbier, A. and Suda, T. (1997) Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. Bone 20: 399-404. https://doi.org/10.1016/S8756-3282(97)00025-2
- Hadjdaksis, D. J. and Androulakis, I. I. (2006) Bone remodeling. Ann. N. Y. Acad. Sci. 1092: 385-396. https://doi.org/10.1196/annals.1365.035
-
Li, C. H., Yang, Z. F., Li, Z. X., Ma, Y., Zhang, L. P. Zheng, C. B., Qiu, W. W., Wu, X. A., Wang, X., Li, H., Tang, J., Qian, M., Li, D., Wang, P., Luo, J. A. and Liu, M. G. (2011) Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-
${\kappa}B$ and MAPK signaling pathways. J. Bone Miner. Res. 26: 644-656. https://doi.org/10.1002/jbmr.242 -
Lee, J. H., Jin, H. X., Shim, H. E., Kim, H. N., Ha, H. I. and Lee, Z. H. (2010) Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-
${\kappa}B$ signal. E. Mol. Pharmacol. 77: 17-25. https://doi.org/10.1124/mol.109.057877 - Teitelbaum, S. L. (2007) Osteoclasts: What do they do how do they do it? Am. J. Pathol. 170: 427-435. https://doi.org/10.2353/ajpath.2007.060834